Veracyte 미래 성장

Future 기준 확인 3/6

Veracyte (는) 각각 연간 46.2% 및 9.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 45.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 6.6% 로 예상됩니다.

주요 정보

46.2%

수익 성장률

45.9%

EPS 성장률

Biotechs 수익 성장	27.6%
매출 성장률	9.1%
향후 자기자본 수익률	6.6%
애널리스트 커버리지	Good
마지막 업데이트	16 Dec 2024

최근 미래 성장 업데이트

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09

Recent updates

Veracyte: Getting Frothy

Dec 11

Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Dec 01

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Aug 18

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Jul 02

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Jun 06

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

수익 및 매출 성장 예측

NasdaqGM:VCYT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	539	63	93	115	9
12/31/2025	487	37	84	101	11
12/31/2024	443	28	90	63	11
9/30/2024	425	-9	56	66	N/A
6/30/2024	400	-54	40	50	N/A
3/31/2024	375	-68	26	37	N/A
12/31/2023	361	-74	34	44	N/A
9/30/2023	343	-50	29	38	N/A
6/30/2023	329	-29	23	31	N/A
3/31/2023	311	-30	7	14	N/A
12/31/2022	297	-37	-1	8	N/A
9/30/2022	284	-43	-1	6	N/A
6/30/2022	268	-49	-10	-2	N/A
3/31/2022	251	-48	-7	0	N/A
12/31/2021	220	-76	-37	-32	N/A
9/30/2021	187	-73	-43	-38	N/A
6/30/2021	157	-63	-39	-35	N/A
3/31/2021	123	-65	-48	-45	N/A
12/31/2020	117	-35	-13	-10	N/A
9/30/2020	113	-34	-13	-10	N/A
6/30/2020	113	-31	-16	-13	N/A
3/31/2020	122	-22	-10	-8	N/A
12/31/2019	120	-13	-6	-3	N/A
9/30/2019	116	-8	-8	-6	N/A
6/30/2019	109	-12	-9	-6	N/A
3/31/2019	101	-16	-10	-7	N/A
12/31/2018	92	-23	-15	-14	N/A
9/30/2018	86	-28	-20	-18	N/A
6/30/2018	80	-31	N/A	-21	N/A
3/31/2018	76	-32	N/A	-23	N/A
12/31/2017	72	-31	N/A	-24	N/A
9/30/2017	71	-27	N/A	-22	N/A
6/30/2017	72	-26	N/A	-25	N/A
3/31/2017	68	-29	N/A	-27	N/A
12/31/2016	65	-31	N/A	-28	N/A
9/30/2016	61	-35	N/A	-27	N/A
6/30/2016	55	-38	N/A	-23	N/A
3/31/2016	52	-36	N/A	-27	N/A
12/31/2015	50	-34	N/A	-27	N/A
9/30/2015	48	-34	N/A	-33	N/A
6/30/2015	45	-33	N/A	-35	N/A
3/31/2015	42	-30	N/A	-30	N/A
12/31/2014	38	-29	N/A	-28	N/A
9/30/2014	33	-27	N/A	-22	N/A
6/30/2014	29	-26	N/A	-21	N/A
3/31/2014	25	-25	N/A	-19	N/A
12/31/2013	22	-26	N/A	-19	N/A

애널리스트 미래 성장 예측

수입 대 저축률: VCYT 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: VCYT (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: VCYT 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: VCYT 의 수익(연간 9.1% ) US 시장( 9.1% 보다 느리게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: VCYT 의 수익(연간 9.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: VCYT 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 6.6 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 12:12
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Veracyte, Inc. 18 애널리스트 중 11 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Sung Ji Nam	BTIG
Bryan Brokmeier	Cantor Fitzgerald & Co.
Matthew Sykes	Goldman Sachs

Veracyte 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Veracyte, Inc. Raises Earnings Guidance for the Full Year 2024

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Consensus EPS estimates upgraded to US$0.052 loss

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Forecast to breakeven in 2025

Recent updates

Veracyte: Getting Frothy

Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Veracyte, Inc. Raises Earnings Guidance for the Full Year 2024

Veracyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Veracyte, Inc. Presented New Data At Astro 2024 Show That Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men

Veracyte, Inc. Announces New Data from a Phase 3 Trial of the Multi-Center, Randomized Stampede Clinical Trial

Veracyte, Inc. Announces New Board Appointments

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Veracyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Consensus EPS estimates upgraded to US$0.052 loss

New major risk - Revenue and earnings growth

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Veracyte, Inc., Annual General Meeting, Jun 12, 2024

Veracyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of C2i Genomics, Inc.

Veracyte, Inc. (NasdaqGM:VCYT) has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023

Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023

Veracyte, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer

Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Consensus estimates of losses per share improve by 11%

Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Veracyte, Inc. Announces New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Independent Director notifies of intention to sell stock

Veracyte Announces That New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Co-Founder & Executive Chairwoman notifies of intention to sell stock

Co-Founder & Executive Chairwoman notifies of intention to sell stock

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Announces New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Veracyte, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Co-Founder & Executive Chairwoman exercised options and sold US$682k worth of stock

Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer

Co-Founder & Executive Chairwoman exercised options and sold US$1.4m worth of stock

Independent Director recently sold US$181k worth of stock

Consensus estimates of losses per share improve by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Raises Revenue Guidance for the Year 2022

Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior

New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer